Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Apr 21, 2021 7:15pm
255 Views
Post# 33042001

Has To Be More News !!!

Has To Be More News !!!I am curious of explanation on name change ...if not bought out or took over why choose a name so confusing with another already out there (Claritas)..maybe this is why stk price is being kept down ..what work did we have done last year to current to receive the Australian tax rebate ..730k ?? last yr amount was paid out for services of sort ?? this was mentioned in a previous nr...covance did our animal testing ...any chance that we did testing for nasal spray and next nr will be on IND and or FDA...which in a previous nr I believe they were applying for IND...or possible chance of sale on GVHD ....well by April 28 we will get notified about all the particulars for June 17 meeting....unless they advise more re financing I find it hard to accept that the tax rebate is sufficient enough to move us forward unless the inevitable.. in that case I will not be voting yes...this is imo ...so I guess will wait to see what they advise us with ...glta
<< Previous
Bullboard Posts
Next >>